We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Survival outcomes of patients with stage III colorectal cancer aged ≥ 80 years who underwent curative resection: the HiSCO-04 prospective cohort study.
- Authors
Mochizuki, Tetsuya; Shimomura, Manabu; Nakahara, Masahiro; Adachi, Tomohiro; Ikeda, Satoshi; Saito, Yasufumi; Shimizu, Yosuke; Kochi, Masatoshi; Ishizaki, Yasuyo; Yoshimitsu, Masanori; Takakura, Yuji; Shimizu, Wataru; Sumitani, Daisuke; Kodama, Shinya; Fujimori, Masahiko; Oheda, Mamoru; Kobayashi, Hironori; Akabane, Shintaro; Yano, Takuya; Ohdan, Hideki
- Abstract
Background: The efficacy of adjuvant chemotherapy in elderly patients aged ≥ 80 years with stage III colorectal cancer remains unclear. In parallel with a multicenter prospective phase II trial evaluating the efficacy of uracil-tegafur and leucovorin as adjuvant chemotherapy (HiSCO-03), we conducted a prospective observational study of these patients to assess survival outcomes, including those ineligible for chemotherapy. Methods: This multi-institutional prospective cohort study included 17 institutions in Hiroshima, Japan. Patients aged ≥ 80 years with stage III colorectal cancer who underwent curative resection were enrolled. The primary endpoint was 3-year disease-free survival, and the secondary endpoints were 3-year overall and relapse-free survival. Propensity score matching was used to assess the effects of adjuvant chemotherapy on survival outcomes. Results: A total of 214 patients were analyzed between 2013 and 2018, including 99 males and 115 females with a median age of 84 years (range 80–101 years). Recurrence occurred in 58 patients and secondary cancers were observed in 17. The 3-year disease-free, overall, and relapse-free survival rates were 63.3%, 76.9%, and 62.9%, respectively. Adjuvant chemotherapy was administered to 65 patients with a completion rate of 52%. In a study of 80 patients that adjusted for background factors using propensity score matching, patients who completed the planned treatment showed improved disease-free survival (3-year disease-free survival: completed, 80.0%; not received, 65.5%; and discontinued, 56.3%; p = 0.029). Conclusions: Completion of adjuvant chemotherapy may improve the prognosis of patients with colorectal cancer aged ≥ 80 years, although the number of patients who would benefit from it is limited.
- Subjects
HIROSHIMA-shi (Japan); SURVIVAL rate; COLORECTAL cancer; COHORT analysis; PROPENSITY score matching; PROGRESSION-free survival
- Publication
International Journal of Clinical Oncology, 2024, Vol 29, Issue 2, p159
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-023-02440-9